It wouldn’t be surprising at this stage, if it gets rejected. Its already taken so long that even if it gets approved in the first half of 2026, not many savvy investors will take them seriously. Proper reimbursement support is unlikely because it appears data is not convincing at all. Otherwise, the regulatory approval wouldn't have taken this long, particularly in the country where they have the most political and clinical community support.
So it’s not looking good, either way.
Shorts and LP’s financiers will continue to make a ton of money off the bag holders as endless dilution in pennies continue.
Market Data 
Markets 
AI
